IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-443-6209
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees56
Next Earnings DateN/A
OptionableNot Optionable
IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions
What is IDEAYA Biosciences' stock symbol?
IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."
What price target have analysts set for IDYA?
3 brokers have issued twelve-month target prices for IDEAYA Biosciences' shares. Their predictions range from $14.00 to $20.00. On average, they expect IDEAYA Biosciences' stock price to reach $16.3333 in the next year. This suggests a possible upside of 105.5% from the stock's current price. View Analyst Price Targets for IDEAYA Biosciences.
What is the consensus analysts' recommendation for IDEAYA Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEAYA Biosciences.
Has IDEAYA Biosciences been receiving favorable news coverage?
Headlines about IDYA stock have trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IDEAYA Biosciences earned a daily sentiment score of -2.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for IDEAYA Biosciences.
Who are some of IDEAYA Biosciences' key competitors?
Some companies that are related to IDEAYA Biosciences include Vital Therapies (VTL), Morphic (MORF), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Aurinia Pharmaceuticals (AUPH), Stemline Therapeutics (STML), Akero Therapeutics (AKRO), Organogenesis (ORGO), TherapeuticsMD (TXMD), Revance Therapeutics (RVNC), GlycoMimetics (GLYC), CytomX Therapeutics (CTMX), Akorn (AKRX) and Synthorx (THOR).
What other stocks do shareholders of IDEAYA Biosciences own?
Who are IDEAYA Biosciences' key executives?
IDEAYA Biosciences' management team includes the folowing people:
- Mr. Yujiro S. Hata, Co-Founder, CEO, Pres & Director (Age 45)
- Mr. Jeffrey Hager, Sr. VP, CTO, Head of Target Discovery & External Innovation (Age 55)
- Mr. Paul A. Stone, Sr. VP, Gen. Counsel & Head of Operations (Age 55)
- Mr. Michael P. Dillon, Sr. VP, Chief Scientific Officer & Head of Research (Age 52)
- Dr. Julie Hambleton, Sr. VP, Chief Medical Officer & Head of Devel. (Age 61)
When did IDEAYA Biosciences IPO?
(IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.
When did the company's quiet period expire?
IDEAYA Biosciences' quiet period expired on Tuesday, July 2nd. IDEAYA Biosciences had issued 5,000,000 shares in its public offering on May 23rd. The total size of the offering was $50,000,000 based on an initial share price of $10.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of IDEAYA Biosciences?
Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEAYA Biosciences' stock price today?
One share of IDYA stock can currently be purchased for approximately $7.95.
How big of a company is IDEAYA Biosciences?
What is IDEAYA Biosciences' official website?
How can I contact IDEAYA Biosciences?
IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-6209 or via email at [email protected]
MarketBeat Community Rating for IDEAYA Biosciences (NASDAQ IDYA)
MarketBeat's community ratings are surveys of what our community members think about IDEAYA Biosciences and other stocks. Vote "Outperform" if you believe IDYA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDYA will underperform the S&P 500 over the long term. You may vote once every thirty days.
